Cell and Gene Therapy World Market and Market Potential presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:
The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.
- Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
- Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
- Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
- Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
- U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
- Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
- Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
- Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
Scope
The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.
The following conditions/disorders are covered:
Dermatology, including:
- Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Skin cells)
- Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
- Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
- Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
Cardiovascular and Blood Disorders, including:
- Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
- Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
- Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
Oncology, including:
- Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
- Oncology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
- Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, ROW)
- Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
Ophthalmic Conditions, including:
- Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
- Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, Other countries)
Musculoskeletal Conditions and Disorders, including:
- Musculoskeletal Cell Therapy Market, Estimated 2021 and Projected 2026 and 2031 ($ millions)
- Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
- Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
- Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
Other Conditions, including:
- Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
- Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARYOVERVIEW
SCOPE AND METHODOLOGY MARKET
OVERVIEW AND POTENTIAL
- Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2021-2031
CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY
INTRODUCTION
- Cell Therapy
- Table 2-1: Adult vs. Embryonic Stem Cells
- Gene Therapy
- Table 2-2: Somatic vs. Germ Line Gene Therapy
- Viral Vector System and New Developments
- Table 2-3: Selected Examples of Viruses in Gene Therapy
- Figure 2-1: Viral Vector Use in Commercialized Cell and Gene Therapies
- Non-viral Systems for Transporting Genes
- Gene Editing
- Table 2-4: Cell Therapy vs Gene Therapy
- Leukapheresis
- Activation
- Transduction
- Expansion
- Table 2-5: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
- Figure 2-2: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
- Table 2-6: Selected Recent Viral Vector Company Expansion
REIMBURSEMENT
LOGISTICS
MERGERS AND ACQUISITIONS
- Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
- Table 2-8: Selected Company Partnerships, Agreements and Collaborations in the Cell and Gene
- Therapy Market
- Table 2-9: Recent Cell and Gene Therapy Recent Financing Deals
- Figure 2-3: FDA Cell & Gene Therapy Percent of Projects with Orphan Drug and/or Fast Track
- Status
Orphan Drug
Breakthrough Therapy
Accelerated Approval Priority Review
- Table 2-10: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
- Individualized Gene Therapy Approval Process
- Figure 2-4: Global Cell and Gene Therapy Development Progress (phase I through phase III), as of January 2022
- Figure 2-5: Global Cell and Gene Therapy Development Progress by Phase, as of January 2022
- Figure 2-6: Global Development of Cell and Gene Therapies by Target
- Figure 2-7: Global Development Activity of Cell and Gene Therapies by Country, as of January 2022
- Table 2-11: Phase III Development - Cell and Gene Therapies, Select Projects
- Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)
- Hospitals
- Research Institutes
- Wound Care Centers
- Cancer Centers
CHAPTER 3: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY OVERVIEW
- Table 3-1: Wound Prevalence by Type
- Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2021-2031 ($ millions)
- Adipocel
- Apligraf
- CureSkin
- Dermagraft
- Epicel
- Grafix
- Holoderm
- Kaloderm
- KeraHeal/KeraHeal-Allo
- LaViv
- Orcel
- Quencell
- RECELL
- Rosmir
- Stempeutics/Cutisera
- StrataGraft
- Stravix
- TransCyte
- Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
- Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2021
- Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase, January 2022 Data
- Table 3-4: Dermatology Cell and Gene Therapies in Development by Method, January 2022 Data Phase III Development
- Table 3-5: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2022
- Table 3-6: Orphan Drug, Fast Track and Breakthrough Designations for Dermatology Cell and Gene Therapies in Development (Phase I through III), through January 2022
- Table 3-7: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
- Figure 3-3: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%) Dermatology Cell and Gene Therapy Market by Indication
- Table 3-8: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2031 ($ millions)
- Figure 3-4: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2021
- Table 3-9: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2031 ($ millions)
- Figure: 3-5: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)
- Table 3-10: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
CHAPTER 4: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS
OVERVIEW
- Cardiovascular Disease
- Selected Blood Disorders
MARKET OUTLOOK
- Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2021-2031, ($ millions)
PRINCIPAL PRODUCTS
- Collategene
- Hearticellgram
- HeartSheet
- Leqvio
- Neovasculgen
- Stempeucel
- Zynteglo
- Cord Blood Products
- Table 4-1: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
- Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2021
TRENDS IN RESEARCH AND DEVELOPMENT
- Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase, January 2022 Data
- Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method, January 2022 Data
- Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy
- Developments, through January 2022
- Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood
- Disorder Cell and Gene Therapies in Development (Phase I through III), through January 2022
MARKET BREAKDOWN OF CELL AND GENE THERAPIES
- Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
- Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)
- Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)
REGIONAL MARKET SUMMARY
- Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2021
- Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
- Figure: 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)
COMPETITOR SUMMARY
CHAPTER 5: CELL AND GENE THERAPY MARKETS IN ONCOLOGY
OVERVIEW
- Biochemistry of Cancer Cells
CAUSES OF CANCER GROWTH
- Environmental Factors, DNA, RNA
- Table 5-1: Virus Association with Human Cancer
- Cellular Oncogenes
- Tumor Suppressor Genes
GLOBAL CANCER BURDEN
- Figure 5-1: Estimated Number of New Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
- Figure 5-2: Incidence of Cancer by Type, 2020
- Figure 5-3: Distribution of Cancer Incidence by Type, 2020
MARKET OUTLOOK
- Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2021-2031 ($ millions)
PRINCIPAL PRODUCTS
- Abecma
- APCeden
- Breyanzi
- CreaVax-RCC
- Gendicine
- Imlygic
- Immuncell-LC
- Kymriah
- Provenge
- Tecartus
- Yescarta
- Table 5-2: Cell and Gene Therapy in Oncology
- Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2021
TRENDS IN RESEARCH AND DEVELOPMENT
- Table 5-3: Oncology Cell and Gene Therapies in Development by Phase, January 2022 Data
- Table 5-4: Oncology Cell and Gene Therapies in Development by Method, January 2022 Data
- Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, January 2022 Data (Phase I through Phase III)
Phase III Development
- Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through January 2022
Orphan Drug, Fast Track, Breakthrough Designations
- Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene
- Therapies in Development (Phase I through III), FDA Reported, through March 2020
MARKET BREAKDOWN OF CELL AND GENE THERAPIES
- Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
- Figure 5-7: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)
Oncology Cell and Gene Therapy Market by Cancer Type
- Table 5-8: Oncology Cell and Gene Therapy Market by Cancer Type, Estimated 2021 and Projected 2031 ($ millions)
- Figure 5-8: Oncology Cell and Gene Therapy Market by General Indication (leukemia, lymphoma, undefined blood cancer, prostate cancer, melanoma, multiple myeloma, other cancers), Estimated 2021 (%)
REGIONAL MARKET SUMMARY
- Figure 5-9: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2021
- Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
- Figure: 5-10: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)
COMPETITOR SUMMARY
- Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
CHAPTER 6: CELL AND GENE THERAPY MARKETS IN OPHTHALMIC CONDITIONS
OVERVIEW
MARKET OUTLOOK
- Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2021-2031 ($ millions)
PRINCIPAL PRODUCTS
Holoclar
Luxturna
- Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions
TRENDS IN RESEARCH AND DEVELOPMENT
- Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase, January 2022 Data
- Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method, January 2022
- Data
Phase III Development
- Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through January 2022
Orphan Drug, Fast Track, Breakthrough Designations
- Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022
MARKET BREAKDOWN OF CELL AND GENE THERAPIES
- Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
- Figure 6-2: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)
REGIONAL MARKET SUMMARY
- Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
- Figure: 6-3: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)
COMPETITOR SUMMARY
CHAPTER 7: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS
OVERVIEW
MARKET OUTLOOK
- Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 20212031 ($ millions)
PRINCIPAL PRODUCTS
- AlloStem
- BIO4
- Carticel
- Cartiform
- CartiLife
- Cartistem
- Chondron
- JACC
- MACI
- Ortho-ACI and Ortho-ATI
- Ossron
- Osteocel and Osteoplus
- Spherox
- Trinity Elite and Trinity Evolution
- Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
- Figure 7-2: Musculoskeletal Cell and Gene Therapy Approvals by Year or Year Range, through 2021
TRENDS IN RESEARCH AND DEVELOPMENT
- Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase, January 2022 Data
- Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method, January 2022
- Data
Phase III Development
- Table 7-4: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2022
MARKET BREAKDOWN OF CELL AND GENE THERAPIES
- Table 7-5: Musculoskeletal Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Musculoskeletal Cell and Gene Therapy Market by Indication
- Table 7-6: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2013 and Projected 2031($ millions)
- Figure 7-3: Musculoskeletal Cell and Gene Therapy Market by General Indication (cartilage treatment, bone treatment and other indications), Estimated 2021 (%)
REGIONAL MARKET SUMMARY
- Figure 7-4: Musculoskeletal Cell and Gene Therapy Approvals by Country/Region, through 2021
- Table 7-7: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 20 and Projected 2031 ($ millions)
- Figure: 7-5: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)
COMPETITOR SUMMARY
- Table 7-8: Musculoskeletal Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
CHAPTER 8: CELL AND GENE THERAPY MARKETS IN NEUROLOGICAL-RELATED DISORDERS
OVERVIEW
MARKET OUTLOOK
- Figure 8-1: Cell and Gene Therapy Markets in Neurological-Related Conditions, 2021-2031, ($ millions)
PRINCIPAL PRODUCTS
- Libmeldy
- NeuroNata-R
- Onpattro
- SKYSONA
- Stemirac
- Zolgensma
- Table 8-1: Cell and Gene Therapy in Neurological Diseases and Disorders
TRENDS IN RESEARCH AND DEVELOPMENT
Phase III Development
- Table 8-2: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2022
Orphan Drug, Fast Track, Breakthrough Designations
- Table 8-3: Orphan Drug, Fast Track and Breakthrough Designations for Neurological Cell and Gene
- Therapies in Development (Phase I through III), FDA Reported, through January 2022
MARKET BREAKDOWN OF CELL AND GENE THERAPIES
- Table 8-4: Neurological Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
- Figure 8-2: Neurological Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)
REGIONAL MARKET SUMMARY
- Table 8-5: Neurological Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
- Figure 8-3: Neurological Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)
COMPETITOR SUMMARY
- Table 8-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
CHAPTER 9: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS
OVERVIEW
MARKET OUTLOOK
- Figure 9-1: Cell and Gene Therapy Markets in Other Conditions, 2021-2031, ($ millions)
PRINCIPAL PRODUCTS
- Alofisel
- Cupistem
- Givlaari
- Glybera
- Oxlumo
- Rethymic
- Ryplazim
- Strimvelis
- Temcell/Prochymal/Ryoncil
- Table 9-1: Cell and Gene Therapy in Other Diseases and Disorders
TRENDS IN RESEARCH AND DEVELOPMENT
MARKET BREAKDOWN OF CELL AND GENE THERAPIES
- Table 9-2: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
- Figure 9-2: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021(%)
REGIONAL MARKET SUMMARY
- Table 9-3: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 20 and Projected 2031($ millions)
- Figure 9-3: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)
COMPETITOR SUMMARY
CHAPTER 10: CELL AND GENE THERAPY MARKET REVIEW
MARKET INFLUENCES
Global Demographics
- Table 10-1: Global Population, through 2050 (population in millions)
- Figure 10-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Cost Containment
- Table 10-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies
CELL AND GENE THERAPY AND VIRAL VECTOR SHORTAGES
GLOBAL MARKET SUMMARY.
- Table 10-3: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions)
- Figure 10-2: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031
- Figure 10-3: Cell and Gene Therapy Market, Distribution of Sales by Product Segment, 2021
CELL VS. GENE THERAPY MARKETS
- Table 10-4: Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions)
- Figure 10-4: Cell and Gene Therapy Market, Distribution of Sales by Method, 2021
REGIONAL MARKET OVERVIEW
- Table 10-5: Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions)
UNITED STATES
- Table 10-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 20212031 ($ millions)
- Figure 10-5: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
- Table 10-7: Major Cell and Gene Therapy Product Approvals, FDA
EUROPE/EUROPEAN UNION
- Table 10-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2021-2031 ($ millions)
- Figure 10-6: Europe Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
- Table 10-9: Major Cell and Gene Therapy Approvals by EMA
OTHER COUNTRIES
- Table 10-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2021-2031 ($ millions)
- Figure 10-7: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
- Table 10-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
COMPETITOR RANKING IN CELL AND GENE THERAPY MARKETS
- Table 10-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
- Figure 10-8: Cell and Gene Therapy Market Share Estimates, 2021
CHAPTER 11: MARKET PARTICIPANTS
LEADING INFLUENCERS
ADVAXIS, INC. (BIOSIGHT THERAPEUTICS)
- Table 11-1: Advaxis Corporate Summary
- Company Summary
- Products
- Table 11-2: AlloSource Corporate Summary
- Company Summary
- Products
- Table 11-3: Alnylam Pharmaceuticals Corporate Summary
- Company Summary
- Products
- Table 11-4: Amgen Corporate Summary
- Company Summary
- Products
- Table 11-5: AnGes Corporate Summary
- Company Summary
- Products
- Table 11-6: Anterogen Corporate Summary
- Company Summary
- Products
- Table 11-7: Atara Biotherapeutics Corporate Summary
- Company Summary
- Products
- Table 11-8: Athersys Corporate Summary
- Company Summary
- Products
- Table 11-9: BioCardia Summary
- Company Summary
- Products
- Table 11-10: Biogen Corporate Summary
- Company Summary
- Products
- Table 11-11: BioMarin Pharmaceuticals Corporate Summary
- Company Summary
- Products
- Table 11-12: bluebird bio Corporate Summary
- Company Summary
- Products
- Table 11-13: BrainStorm Cell Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-14: Bristol-Myers Squibb Corporate Summary
- Company Summary
- Products
- Table 11-15: Caladrius Biosciences Corporate Summary
- Company Summary
- Products
- Table 11-16: Candel Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-17: Castle Creek Corporate Summary
- Company Summary
- Products
- Table 11-18: Celyad Oncology Corporate Summary
- Company Summary
- Products
- Table 11-19: Cook Myosite Corporate Summary
- Company Summary
- Products
- Table 11-20: Cytori Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-21: Dendreon Corporate Summary
- Company Summary
- Products
- Table 11-22: FerGene Corporate Summary
- Company Summary
- Products
- Table 11-23: Gamida Cell Corporate Summary
- Company Summary
- Products
- Table 11-24: GenSight Biologics Corporate Summary
- Company Summary
- Products
- Table 11-25: Gilead Sciences Corporate Summary
- Company Summary
- Products
- Table 11-26: Gradalis Corporate Summary
- Company Summary
- Products
- Table 11-27: Helixmith Corporate Summary
- Company Summary
- Products
- Table 11-28: Inovio Pharmaceuticals Corporate Summary
- Company Summary
- Products
- Table 11-29: Kiadis Pharma Corporate Summary
- Company Summary
- Products
- Table 11-30: Medeor Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-31: MEDIPOST Corporate Summary
- Company Summary
- Products
- Table 11-32: MeiraGTxCorporate Summary
- Company Summary
- Products
- Table 11-33: Merck & Co. Corporate Summary
- Company Summary
- Products
- Table 11-34: Mesoblast Corporate Summary
- Company Summary
- Products
- Table 11-35: Neurotech Corporate Summary
- Company Summary
- Products
- Table 11-36: Northwest Biotherapeutics Corporate Summary
- Company Summary
- Products
- Table 11-37: Novartis Corporate Summary
- Company Summary
- Products
- Table 11-38: NuVasive Biologics Corporate Summary
- Company Summary
- Products
- Table 11-39: Orchard Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-40: Organogenesis Corporate Summary
- Company Summary
- Products
- Table 11-41: Orthofix Corporate Summary
- Company Summary
- Products
- Table 11-42: Osiris Corporate Summary
- Company Summary
- Products
- Table 11-43: Pharmicell Corporate Summary
- Company Summary
- Products
- Table 11-44: Pluristem Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-45: Sangamo Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-46: Sanofi Corporate Summary
- Company Summary
- Products
- Table 11-47: Sotio Corporate Summary
- Company Summary
- Products
- Table 11-48: Spark Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-49: Tessa Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-50: UniQure Corporate Summary
- Company Summary
- Products
- Table 11-51: VBL Therapeutics Corporate Summary
- Company Summary
- Products
- Table 11-52: Vericel Corporate Summary
- Company Summary
- Products
Samples
LOADING...
Companies Mentioned
- Advaxis, Inc. (Biosight Therapeutics)
- Allosource
- Alnylam Pharmaceuticals, Inc.
- Amgen
- Anges Inc.
- Anterogen Co Ltd.
- Atara Biotherapeutics
- Athersys, Inc
- Biocardia
- Biogen, Inc.
- Biomarin Pharmaceuticals
- Bluebird Bio, Inc.
- Brainstorm Cell Therapeutics
- Bristol-Myers Squibb
- Caladrius Biosciences
- Candel Therapeutics
- Castle Creek Biosciences
- Celyad Oncology
- Cook Myosite, Inc
- Cytori Therapeutics, Inc
- Dendreon Pharmaceuticals LLC
- Fergene, Inc/Ferring Pharmaceuticals
- Gamida Cell Ltd.
- Gensight Biologics S.A.
- Gilead Sciences, Inc.
- Gradalis, Inc
- Helixmith
- Inovio Pharmaceuticals, Inc.
- Kiadis Pharma B.V. (Sanofi)
- Medeor Therapeutics
- Medipost Co, Ltd.
- Meiragtx
- Merck & Co. Inc.
- Mesoblast Ltd.
- Neurotech Pharmaceuticals. Inc.
- Northwest Biotherapeutics, Inc.
- Novartis AG
- Nuvasive Biologics
- Orchard Therapeutics
- Organogenesis
- Orthofix
- Osiris Therapeutics, Inc.( Part of Smith & Nephew)
- Pharmicell
- Pluristem Therapeutics, Inc.
- Sangamo Therapeutics
- Sanofi
- Sotio A.S
- Spark Therapeutics
- Tessa Therapeutics, Ltd.
- Uniqure N.V.
- VBL Therapeutics (Vascular Biogenics Ltd.)
- Vericel Corporation